BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Narayanan S, Vicent S, Ponz-sarvisé M. PDAC as an Immune Evasive Disease: Can 3D Model Systems Aid to Tackle This Clinical Problem? Front Cell Dev Biol 2021;9:787249. [DOI: 10.3389/fcell.2021.787249] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Markowski A, Zaremba-Czogalla M, Jaromin A, Olczak E, Zygmunt A, Etezadi H, Boyd BJ, Gubernator J. Novel Liposomal Formulation of Baicalein for the Treatment of Pancreatic Ductal Adenocarcinoma: Design, Characterization, and Evaluation. Pharmaceutics 2023;15. [PMID: 36678808 DOI: 10.3390/pharmaceutics15010179] [Reference Citation Analysis]
2 Limbu KR, Chhetri RB, Oh YS, Baek DJ, Park EY. Mebendazole Impedes the Proliferation and Migration of Pancreatic Cancer Cells through SK1 Inhibition Dependent Pathway. Molecules 2022;27. [PMID: 36500220 DOI: 10.3390/molecules27238127] [Reference Citation Analysis]
3 Zhou X, Ni Y, Liang X, Lin Y, An B, He X, Zhao X. Mechanisms of tumor resistance to immune checkpoint blockade and combination strategies to overcome resistance. Front Immunol 2022;13:915094. [DOI: 10.3389/fimmu.2022.915094] [Reference Citation Analysis]
4 Zhu Z, Chen L, Miao D, Jin Y, Wu Q. Integrated analysis of senescence-associated genes in pancreatic ductal adenocarcinoma. Front Genet 2022;13:941389. [DOI: 10.3389/fgene.2022.941389] [Reference Citation Analysis]
5 Sally Á, Mcgowan R, Finn K, Moran BM. Current and Future Therapies for Pancreatic Ductal Adenocarcinoma. Cancers 2022;14:2417. [DOI: 10.3390/cancers14102417] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]